<DOC>
	<DOCNO>NCT00950807</DOCNO>
	<brief_summary>The study evaluate dose response , safety , pharmacokinetics GSK573719 compare placebo subject COPD .</brief_summary>
	<brief_title>GSK573719 Dose Ranging Study Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , double-dummy , placebo-controlled , three-way cross-over , incomplete block design study evaluation 5 dos GSK573719 administer once-daily 3 dos GSK573719 administer twice-daily 14 day subject COPD include tiotropium open-label active control . The pharmacokinetic profile GSK573719 also evaluate .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>A sign date write informed consent prior study participation Males females nonchildbearing potential 40 80 year age COPD diagnosis 10 packyears history great cigarette smoking Postbronchodilator FEV1/FVC ratio 0.70 less Postbronchodilator FEV1 35 70 % predict normal Asthma Other significant respiratory disorder besides COPD , include alpha1 deficiency Previous lung resection surgery Use oral steroid antibiotic COPD exacerbation within 6 week screen Hospitalization COPD pneumonia within 3 month screen Any significant disease would put subject risk study participation BMI great 35 Pacemaker Significantly abnormal ECG , Holter , clinical lab finding ( include Hepatitis B C ) Cancer Allergy hypersensitivity anticholinergic inhaler excipients Diseases would contraindicate use anticholinergic Use oral corticosteroid within 6 week screen Use longacting betaagonists within 48 hour screen Use tiotropium within 14 day screen Use theophylline antileukotrienes within 48 hour screen Use shortacting bronchodilator within 4 6 hour screen Use investigational medicine within 30 day screen Use high dose inhale corticosteroid Use longterm oxygen therapy , CPAP NIPPV Previous use GSK573719</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Dose range</keyword>
	<keyword>Chronic Bronchitis</keyword>
	<keyword>Long-acting muscarinic antagonist</keyword>
	<keyword>cross-over</keyword>
	<keyword>COPD</keyword>
	<keyword>Emphysema</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease ( COPD )</keyword>
	<keyword>anticholinergic</keyword>
</DOC>